• Featured Product
  • KD/KO Validated

Alpha Galactosidase A Polyclonal antibody

Alpha Galactosidase A Polyclonal Antibody for IHC, IP, WB,ELISA

Host / Isotype

Rabbit / IgG

Reactivity

human, mouse, rat

Applications

WB, IP, IHC,ELISA

Conjugate

Unconjugated

Cat no : 15428-1-AP

Synonyms

Alpha galactosidase A, galactosidase, alpha



Tested Applications

Positive WB detected inMCF-7 cells, HEK-293 cells, HeLa cells
Positive IP detected inHEK-293 cells
Positive IHC detected inhuman liver cancer tissue, human liver tissue, mouse liver tissue
Note: suggested antigen retrieval with TE buffer pH 9.0; (*) Alternatively, antigen retrieval may be performed with citrate buffer pH 6.0

Recommended dilution

ApplicationDilution
Western Blot (WB)WB : 1:500-1:3000
Immunoprecipitation (IP)IP : 0.5-4.0 ug for IP and 1:500-1:2000 for WB
Immunohistochemistry (IHC)IHC : 1:250-1:1000
Sample-dependent, check data in validation data gallery

Product Information

15428-1-AP targets Alpha Galactosidase A in WB, IP, IHC,ELISA applications and shows reactivity with human, mouse, rat samples.

Tested Reactivity human, mouse, rat
Cited Reactivity human, mouse
Host / Isotype Rabbit / IgG
Class Polyclonal
Type Antibody
Immunogen Alpha Galactosidase A fusion protein Ag7609
Full Name galactosidase, alpha
Calculated molecular weight 49 kDa
Observed molecular weight 46-50 kDa
GenBank accession numberBC002689
Gene symbol GLA
Gene ID (NCBI) 2717
Conjugate Unconjugated
Form Liquid
Purification Method Antigen affinity purification
Storage Buffer PBS with 0.02% sodium azide and 50% glycerol pH 7.3.
Storage ConditionsStore at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage.

Background Information

GLA (Alpha-galactosidase A), also named as Melibiase or Agalsidase, belongs to the glycosyl hydrolase 27 family. It catalyzes the hydrolysis of terminal, non-reducing alpha-D-galactose residues in alpha-D-galactosides, including galactose oligosaccharides, galactomannans and galactolipids. The deficient activity of GLA can cause Fabry disease which is an X-linked inborn error of glycosphingolipid metabolis (PMID: 19287194). Enzyme replacement therapy (ERT) with GLA is currently the most effective therapeutic strategy for patients with Fabry disease (PMID: 20398385). In humans, GLA is synthesized as a 50 kDa precursor, which is further processed to a 46 kDa mature form of the protein (PMID: 9883849, 19387866). It also has a homodimer form with the molecular mass of 110 kDa (PMID: 17287429).

Protocols

Product Specific Protocols
WB protocol for Alpha Galactosidase A antibody 15428-1-APDownload protocol
IHC protocol for Alpha Galactosidase A antibody 15428-1-APDownload protocol
IP protocol for Alpha Galactosidase A antibody 15428-1-APDownload protocol
Standard Protocols
Click here to view our Standard Protocols

Publications

SpeciesApplicationTitle
human

Orphanet J Rare Dis

Deep characterization of the anti-drug antibodies developed in Fabry disease patients, a prospective analysis from the French multicenter cohort FFABRY.

Authors - Wladimir Mauhin
human,mouseWB,IHC

J Extracell Vesicles

Extracellular vesicles from recombinant cell factories improve the activity and efficacy of enzymes defective in lysosomal storage disorders.

Authors - Joaquin Seras-Franzoso
  • KO Validated